Edition:
United Kingdom

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

6.95USD
20 Jul 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.95
Open
$6.90
Day's High
$7.00
Day's Low
$6.75
Volume
6,153
Avg. Vol
13,254
52-wk High
$7.45
52-wk Low
$2.78

Latest Key Developments (Source: Significant Developments)

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Proqr reports loss of EUR 0.42 per share​
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Proqr Therapeutics Nv :Proqr announces results for the third quarter of 2017.Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​.  Full Article

ProQR Therapeutics prices public offering
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - ProQR Therapeutics Nv :ProQR prices approximately $20 million underwritten public offering and concurrent registered direct offering of ordinary shares.Pricing of offering of its ordinary shares at a price to public of $3.25 per share​.  Full Article

Proqr announces proposed public offering of ordinary shares
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Proqr Therapeutics Nv :Proqr announces proposed public offering of ordinary shares.Proqr - To use proceeds from both offerings to fund clinical trials, ongoing research & development activities​.  Full Article

ProQR doses first LCA 10 patient in clinical trial of QR-110
Monday, 13 Nov 2017 

Nov 13 (Reuters) - ProQR Therapeutics NV :ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness.ProQR Therapeutics - ‍interim safety and efficacy trial results for QR-110​ from majority of patients after 6 months of treatment are expected in 2018.ProQR Therapeutics - full 12 month treatment data for QR-110 from all patients are expected in 2019​.  Full Article

JDG B.V. reports 10.5 pct passive stake in ProQR Therapeutics NV as on Sept 14
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Proqr Therapeutics Nv :JDG B.V. Reports 10.5 percent passive stake in ProQR Therapeutics NV as on September 14 - SEC Filing‍​.  Full Article

ProQR Therapeutics posts Q2 loss per share of 0.43 euros
Wednesday, 17 Aug 2016 

ProQR Therapeutics NV : Proqr announces results for the second quarter of 2016 .Q2 loss per share eur 0.43.  Full Article

BRIEF-ProQR Announces Q1 Loss Per Share Eur 0.34

* AT MARCH 31, 2018, PROQR HELD CASH AND CASH EQUIVALENTS OF €38.0 MILLION, COMPARED TO €48.1 MILLION AT DECEMBER 31, 2017 Source text for Eikon: Further company coverage: